Paul H. Chapman, MD
Massachusetts General Hospital
Massachusetts General Hospital
Phone: (617) 726-3887
Fax: (617) 724-7632
Paul H. Chapman, MD
Massachusetts General Hospital
EDUCATIONAL TITLES
DF/HCC PROGRAM AFFILIATION
Publications from Harvard Catalyst Profiles
- Lee G, Lamba N, Niemierko A, Kim DW, Chapman PH, Loeffler JS, Curry WT, Martuza RL, Oh KS, Barker FG, Shih HA. Adjuvant Radiation Therapy Versus Surveillance After Surgical Resection of Atypical Meningiomas. Int J Radiat Oncol Biol Phys 2020. PubMed
- Atkins KM, Pashtan IM, Bussière MR, Kang KH, Niemierko A, Daly JE, Botticello TM, Hurd MC, Chapman PH, Oh K, Loeffler JS, Shih HA. Proton Stereotactic Radiosurgery for Brain Metastases: A Single-Institution Analysis of 370 Patients. Int J Radiat Oncol Biol Phys 2018; 101:820-829. PubMed
- Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clin Cancer Res 2015. PubMed
- Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Eur J Cancer 2015; 51:1435-43. PubMed
- Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res 2015. PubMed
- Wattson DA, Tanguturi SK, Spiegel DY, Niemierko A, Biller BM, Nachtigall LB, Bussière MR, Swearingen B, Chapman PH, Loeffler JS, Shih HA. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys 2014; 90:532-9. PubMed
- Halasz LM, Bussière MR, Dennis ER, Niemierko A, Chapman PH, Loeffler JS, Shih HA. Proton Stereotactic Radiosurgery for the Treatment of Benign Meningiomas. Int J Radiat Oncol Biol Phys 2010. PubMed
- Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010; 28:3042-7. PubMed
- Wu AJ, Gomez J, Zhung JE, Chan K, Gomez DR, Wolden SL, Zelefsky MJ, Wolchok JD, Carvajal RD, Chapman PB, Wong RJ, Shaha AR, Kraus DH, Shah JP, Lee NY. Radiotherapy after surgical resection for head and neck mucosal melanoma. Am J Clin Oncol 2010; 33:281-5. PubMed
- Chapman P, Cranmer L, Dixon WG, Hyrich KL, Patterson JR, Symmons DP, Toporcer M, Mastrangelo MJ. The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit? Semin Oncol 2010; 37:11-9. PubMed
- Cacucci F, Yi M, Wills TJ, Chapman P, O'Keefe J. Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model. Proc Natl Acad Sci U S A 2008; 105:7863-8. PubMed
- Chapman PB. Combining a peptide vaccine with high-dose interleukin-2. J Clin Oncol 2008; 26:2250-1. PubMed
- Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008; 26:2299-304. PubMed
- Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P, Ancukiewicz M, Bussiere M, Klibanski A, Loeffler JS. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 2008; 93:393-9. PubMed
- Park JE, Lu SX, Wu DY, Prendes M, Chapman PB. Antibody response to GD3 ganglioside is independent of NKT cells. Cytotherapy 2008; 10:38-44. PubMed
- Park JE, Wu DY, Prendes M, Lu SX, Ragupathi G, Schrantz N, Chapman PB. Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand. Immunology 2008; 123:145-55. PubMed
- Chapman PB. Melanoma vaccines. Semin Oncol 2007; 34:516-23. PubMed
- Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, Zhang Y, Ranganathan R, Chapman PB, Krown SE, Livingston PO, Heywood M, Riviere I, Panageas KS, Terzulli SL, Perales MA. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007; 15:2044-50. PubMed
- Petit JH, Biller BM, Coen JJ, Swearingen B, Ancukiewicz M, Bussiere M, Chapman P, Klibanski A, Loeffler JS. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract 2007; 13:726-34. PubMed
- Chapman PB. Detection of melanoma cells in sentinel lymph nodes by PCR is not yet ready for prime time. Pigment Cell Res 2007; 20:343-4. PubMed
- Verhey LJ, Chen CC, Chapman P, Loeffler J, Curry WT. Single-fraction stereotactic radiosurgery for intracranial targets. Neurosurg Clin N Am 2006; 17:79-97. PubMed